Recursion Pharmaceuticals is trading 4.80% down at $4.07 on October 8, 2026, with no clear company-specific announcement identified to explain the decline.
- News included a company presentation at a healthcare conference and reported ARK purchases; neither establishes a direct reason for the drop.
- Broader indexes are modestly lower, while available biotech-sector indications are limited; the evidence does not establish either as the cause.